Meet the Psychiatrist Leading MDMA-Assisted Therapy in New Zealand
RNZ, Saturday Morning, September 5, 2026
Dr Gary Wynn is one of two psychiatrists just approved to prescribe MDMA in New Zealand, a first in the country’s history and a graduate of Mind Medicine Australia’s world-leading Certificate in Psychedelic-Assisted Therapies (CPAT)™. RNZ’s Saturday Morning caught up with him to talk about what happens next as supervised MDMA-assisted therapy for PTSD begins in New Zealand.
MDMA-Assisted Therapy Gets Official Approval for PTSD Treatment in New Zealand
RNZ Digital reporters, September 4, 2026
New Zealand has become only the second country in the world, after Australia, to approve MDMA-assisted therapy for PTSD. Medsafe has granted approval to two psychiatrists Dr Gary Wynn (Wellington) and Dr Tom Paterson (Auckland), to prescribe pharmaceutical-grade MDMA as part of a supervised, clinic-only treatment programme, following a year-long regulatory process.
The approval builds on a 2023 clinical trial that found significant PTSD symptom reduction versus placebo, with no serious adverse effects. It’s a strong validation of the psychedelic-assisted therapy path Australia has led globally since 2023 and a sign that supervised access to these treatments is gaining international ground.
Could Psilocybin Help People Still Struggling After Lyme Disease?
ScienceAlert, August 30, 2026
A small Johns Hopkins pilot study gave 20 people with lingering post-treatment Lyme disease symptoms two doses of psilocybin under clinical supervision, finding notable improvements in pain, fatigue, sleep and mood that held up at six months. It’s early, preliminary research that still needs larger controlled trials, but it points to a question MMA is watching closely: how far might psychedelic-assisted therapies extend beyond mental health, into other hard-to-treat conditions?
New Brain-Scanning Study Reveals How Psilocybin Reshapes the Mind
The Sydney Morning Herald, August 25, 2026
A major new brain-imaging study from Monash University’s Turner Institute has revealed how psilocybin reshapes brain activity, offering fresh insight into why the experience can feel so profound. Published in Nature, the research found a “hidden level of organisation” behind the psychedelic state, with half of participants describing it as one of the most meaningful experiences of their lives.
What Happens When Adults Can Access Psilocybin Legally, for Wellbeing and Growth?
Oregon Public Broadcasting, August 19, 2026
More than 20,000 Oregonians have used legal psilocybin since the state’s program launched in 2023. A new study followed around 350 of them closely, finding serious adverse events in just 1% of participants and meaningful drops in anxiety, depression and PTSD symptoms for most, another important data point in the growing global evidence base for safe, supported access to these therapies.
How psilocybin alters consciousness to create a sense of ‘oneness’
Scientific American, August 19, 2026
Taking psychedelics can dissolve the boundary between yourself and the rest of the world, leaving a profound sense of oneness. Now scientists have revealed that specific changes to the brain may cause this altered sense of consciousness.
MDMA-Assisted Therapy for PTSD Resubmitted to the FDA, Two Years After Initial Rejection
HCPLive, August 11, 2026
Resilient Pharmaceuticals (formerly MAPS PBC / Lykos Therapeutics) has resubmitted its New Drug Application for MDMA-assisted therapy for PTSD to the FDA, two years after the treatment received a Complete Response Letter in 2024. The resubmission follows new FDA guidance on psychedelic drug trials that addresses many of the concerns raised in their original rejection in 2024.
Promising results from first UK trial of psilocybin for depression
King’s College London, August 6, 2026
First UK Publicly-Funded Trial Shows Promising Results for Psilocybin in Depression.
A landmark randomised controlled trial led by King’s College London, the first of its kind funded by the UK’s National Institute for Health and Care Research, has found that a single dose of psilocybin produced significant improvements in treatment-resistant depression compared to placebo.
Published in Nature Medicine, the results add further weight to the growing global evidence base MMA has long championed.
MDMA-assisted psychotherapy reduces PTSD in 80% of soldiers, Israeli study finds
The Jerusalem Post, August 4, 2026
A new Israeli study conducted at Clalit Health Services’ Emek Medical Center has found that MDMA-assisted psychotherapy led to reduced PTSD symptoms in around 80% of soldiers who took part, with most no longer meeting the diagnostic criteria for PTSD by the end of treatment. The trial reflects a growing global evidence base for trauma-focused, psychedelic-assisted therapies — an area MMA has long championed here in Australia.
Pharma Company Secures Long-Term Patent for Psilocybin-Based Fibromyalgia Treatment
The Australian, July 22, 2026
ASX-listed Entropy Neurodynamics has been granted South African Patent No. 2025/01722, covering methods of treating fibromyalgia with psilocybin and psilocin-based therapies. The patent provides protection until September 2043, spanning treatment methods, dosing protocols, patient selection and clinical frameworks. CEO Jason Carroll said the patent’s claims extend well beyond simply protecting psilocybin’s use, encompassing the broader therapeutic framework and creating what the company calls “indication-level” IP protection. It’s a reminder of how quickly the psychedelic medicine sector is moving commercially, and why independent, evidence-based advocacy for accessible treatment remains as important as ever.
Eli Lilly enters the psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Reuters, July 16, 2026
Pharmaceutical giant Eli Lilly has agreed to acquire psychedelic drug developer AtaiBeckley for up to $3.8 billion, gaining access to its lead nasal spray candidate for treatment-resistant depression. The deal is the latest signal of major pharma’s growing confidence in psychedelic-based mental health treatments, following AbbVie’s similar acquisition of Gilgamesh Pharmaceuticals last year.
Can Psychedelics Reboot Aging Brains? We’re About to Find Out
SingularityHub, June 22, 2026
A groundbreaking new clinical trial from the UC Berkeley Center for the Science of Psychedelics — dubbed PLASTICITY — is investigating whether psilocybin can produce lasting changes in neuroplasticity in healthy adults aged 60 to 85. The trial, which began enrolling participants in late 2025 and aims to dose 20 people by end of 2026, will use advanced MRI scans and psychological testing to assess how psilocybin affects perception, memory, emotion, and brain structure.
Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
British Journal of Pharmacology, June 16, 2026
Psychedelic Therapies Show Promise for Mental Health and Inflammation — A major peer reviewed review published in the British Journal of Pharmacology has found that psychedelic assisted therapies may offer powerful anti-inflammatory benefits alongside their well documented mental health applications. Researchers found that compounds including psilocybin can reduce pro-inflammatory cytokines — with effects lasting up to 7 days from a single dose.
Monash Launches Trial on Psychedelic Therapy for PCS
Mirage News, June 15, 2026
Monash University researchers have launched Australia’s first randomised, double-blind clinical trial investigating psilocybin-assisted therapy for persistent post-concussion symptoms — a condition affecting up to 50% of people who sustain a concussion. The $1.5 million MRFF funded trial adds to the growing body of evidence supporting the potential of psychedelic assisted therapies in treating conditions with few existing treatment options.
Has AI Already Killed How-To Nonfiction? Sales Trends, My Personal Data, and What It Might Mean for the Future
Tim Ferriss, June 12, 2026
In a striking piece of public transparency, bestselling author Tim Ferriss has revealed that AI is decimating sales of prescriptive nonfiction — and argues that the market for information is rapidly being replaced by chatbots. But his conclusion is a powerful one: what cannot be replaced is transformation… a distinction that sits at the very heart of Mind Medicine Australia’s work.
Psychologists question their ‘egregious’ exclusion from leading psychedelic treatment
The Australian, June 9, 2026
A major debate is unfolding in Australia’s mental health sector after the TGA’s late-May expansion of who can participate in psychedelic-assisted therapies — an expansion that notably excluded the majority of psychologists. The Australian Association of Psychologists has described the decision as “egregious” and is now weighing legal options. While clinical psychologists and psychiatrists retain their roles as primary therapists, general and health psychologists — who make up two-thirds of the psychology workforce — have been left out. Mind Medicine Australia continues to monitor these regulatory developments closely, as workforce access remains critical to ensuring patients can receive these life-changing therapies.
Why Psychedelics Are Gaining Support Across The Political Spectrum
Forbes, June 3, 2026
New polling from the UK reveals 68% of adults support the medical use of psilocybin-assisted therapy — a finding consistent across Labour, Conservative, Liberal Democrat, Green and Reform UK voters. The data, published in Forbes, highlights growing international momentum for psychedelic-assisted therapies, with Australia cited as a world leader following its landmark 2023 rescheduling of psilocybin.
VIDEO: Inside the legal MDMA and psilocybin magic mushroom trade
ABC News (The Business), May 26, 2026
A recent news segment offered an inside look at Australia’s growing psychedelic-assisted therapy sector, where psilocybin and MDMA are being manufactured under strict harmaceutical controls and used in supervised clinical settings to treat PTSD and treatment-resistant depression. Patients and clinicians alike are reporting life-changing outcomes, as demand continues to rise following Australia’s landmark 2023 regulatory change.
Five million Australians are on mental health medication. Rebekah is among those asking why
The Age, May 9, 2026
Nearly one in five Australians are on mental health-related prescriptions, around 5 million people, with 67% on antidepressants. Experts and former patients are questioning whether so many Australians need long-term medication for distress that could be better supported in other ways, as prescription numbers rose 37% between 2014–15 and 2023–24.
A psychedelic medicine performs well against depression
AFR, May 3, 2026
On February 17, Compass Pathways, a British biotech, announced strong results in two late-stage trials showing that a synthetic form of psilocybin – the active compound in magic mushrooms – can rapidly relieve symptoms in patients with treatment-resistant depression. If America’s Food and Drug Administration approves the drug, which could happen early next year, it would be the first psychedelic drug in the US to become a fully licensed medicine.